You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

POTASSIUM CITRATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Potassium Citrate, and when can generic versions of Potassium Citrate launch?

Potassium Citrate is a drug marketed by Ut Sw Medctr, Ani Pharms, Ascent Pharms Inc, Bionpharma, Hibrow Hlthcare, Rising, Strides Pharma, Teva Pharms Usa Inc, Torrent, and Zydus Pharms. and is included in ten NDAs.

The generic ingredient in POTASSIUM CITRATE is potassium citrate. There are two hundred and forty drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the potassium citrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Potassium Citrate

A generic version of POTASSIUM CITRATE was approved as potassium citrate by RISING on June 9th, 2006.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for POTASSIUM CITRATE?
  • What are the global sales for POTASSIUM CITRATE?
  • What is Average Wholesale Price for POTASSIUM CITRATE?
Summary for POTASSIUM CITRATE
Drug patent expirations by year for POTASSIUM CITRATE
Drug Prices for POTASSIUM CITRATE

See drug prices for POTASSIUM CITRATE

Recent Clinical Trials for POTASSIUM CITRATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 2/Phase 3
University of UtahPhase 2/Phase 3
Columbia UniversityPhase 2/Phase 3

See all POTASSIUM CITRATE clinical trials

Pharmacology for POTASSIUM CITRATE
Medical Subject Heading (MeSH) Categories for POTASSIUM CITRATE
Anatomical Therapeutic Chemical (ATC) Classes for POTASSIUM CITRATE

US Patents and Regulatory Information for POTASSIUM CITRATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ut Sw Medctr POTASSIUM CITRATE potassium citrate FOR SOLUTION;ORAL 019647-002 Oct 13, 1988 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms Usa Inc POTASSIUM CITRATE potassium citrate TABLET, EXTENDED RELEASE;ORAL 209758-001 Mar 5, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms POTASSIUM CITRATE potassium citrate TABLET, EXTENDED RELEASE;ORAL 203546-001 Aug 6, 2014 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ascent Pharms Inc POTASSIUM CITRATE potassium citrate TABLET, EXTENDED RELEASE;ORAL 214420-003 Feb 5, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms POTASSIUM CITRATE potassium citrate TABLET, EXTENDED RELEASE;ORAL 212779-002 Jan 14, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hibrow Hlthcare POTASSIUM CITRATE potassium citrate TABLET, EXTENDED RELEASE;ORAL 214426-003 Feb 19, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.